Abstract
Purpose: We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods: irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018. Results: Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs. Conclusion: These data underscore the needs for tailored irAE diagnostic and management pathways.
Original language | English (US) |
---|---|
Pages (from-to) | 789-796 |
Number of pages | 8 |
Journal | Cancer Investigation |
Volume | 39 |
Issue number | 10 |
DOIs | |
State | Published - 2021 |
Keywords
- Therapy
- cancer in the elderly
- treatment
ASJC Scopus subject areas
- Oncology
- Cancer Research